ANI Pharmaceuticals Inc (ANIP)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		2.80	2.34	2.14	1.88	1.74	1.83	1.53	1.58	1.58	1.92	2.22	2.24	2.13	2.32	2.67	2.47	2.86	3.05	2.82	3.09
DSO	days	130.21	156.21	170.28	193.85	209.70	199.87	239.13	230.39	231.40	189.96	164.20	162.82	171.70	157.27	136.80	147.80	127.46	119.63	129.45	118.30

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.80
= 130.21

ANI Pharmaceuticals Inc's Days of Sales Outstanding (DSO) has shown some fluctuations over the past 8 quarters. In Q4 2023, the DSO decreased to 121.52 days compared to the previous quarter where it was 145.26 days. This indicates an improvement in the efficiency of the company in collecting receivables from customers. However, the DSO is still higher compared to the same period in the previous year at 190.86 days in Q4 2022.

Looking at the trend over the past quarters, there seems to be some seasonality with DSO typically peaking in the first quarter of the year. It is worth noting that in Q1 2023, the DSO was the highest at 177.78 days, which was a significant increase compared to the previous quarter. This may indicate potential issues with the company's accounts receivables management during that period.

Overall, ANI Pharmaceuticals Inc should continue to monitor and analyze its DSO closely to ensure efficient management of its accounts receivables and improve cash flow performance.